Clinical trials in Poznan – page 33

943 clinical trials in Poznan, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Poznan at a glance

943

clinical trials

Research sites11

Quick filters

943 trials in Poznan

Open in trial search

Seasonal allergy

Not yet recruiting

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Placebo
Sponsor:Probelte Pharma S.L.

Contact Research Centre

Non-small cell lung cancer stage I

Not yet recruiting

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Duchenne muscular dystrophy

Not yet recruiting

Study on the Safety and Effectiveness of DT-DEC01 for Patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo

Study on the Safety and Effectiveness of DT-DEC01 for Patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo

Poland

Participants:0–17 years
Sponsor:Dystrogen Therapeutics Technology Polska Sp. z o.o.

Contact Research Centre

Diffuse large B-cell lymphoma+7

Not yet recruiting

Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Instytut Hematologii I Transfuzjologii

Contact Research Centre

Atrial fibrillation+1

Not yet recruiting

Title: Evaluation of optimal timing for heparin anticoagulation in patients undergoing transseptal heart procedures (TEER or left atrial appendage closure)

Registered drug

Title: Evaluation of optimal timing for heparin anticoagulation in patients undergoing transseptal heart procedures (TEER or left atrial appendage closure)

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Heparin Sodium
Sponsor:Agencja Badań Medycznych

Contact Research Centre

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Etanercept
Sponsor:Mabxience Research S.L.

Contact Research Centre

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Intensity Therapeutics Inc.

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Anaemia of chronic disease

Not yet recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Darbepoetin Alfa
Sponsor:Genexine Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Malignant peritoneal neoplasm+2

Not yet recruiting

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Agencja Badań Medycznych

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Poznan

What the registry says about research in the country

01 Immunology & Infectious Diseases

Clinical trials focusing on meningococcal vaccines and respiratory syncytial virus prevention. Studies include testing new conjugate vaccines in infants and evaluating immune responses in older adults.

Meningococcal infection prevention
RSV vaccination studies
Vaccine immunogenicity assessment

Multiple age groups are being studied to ensure comprehensive protection against infectious diseases.

02 Dermatology & Rheumatology

Innovative research into psoriatic conditions and inflammatory skin disorders. Studies evaluating new treatments for plaque psoriasis and psoriatic arthritis.

Moderate to severe plaque psoriasis
Psoriatic arthritis treatments
Atopic dermatitis therapy

Focus on developing targeted therapies for chronic inflammatory skin conditions.

03 Oncology

Advanced research in bladder cancer and other oncological conditions. Studies combining immunotherapy with traditional treatments for enhanced efficacy.

Non-muscle invasive bladder cancer
Metastatic prostate cancer
Gastric cancer treatments

Investigating novel combination therapies and targeted treatments for various cancer types.

04 Chronic Diseases

Comprehensive studies addressing chronic kidney disease, obesity, and cardiovascular conditions. Research focuses on innovative treatment approaches and disease management.

Heart failure prevention
Obesity management
Chronic kidney disease treatment

Evaluating new therapeutic options for long-term disease management and prevention.

Back to Poland All countries